135 related articles for article (PubMed ID: 23214246)
1. [Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
Feng JY; Wu CQ; Zhang P; Wang SJ; Zheng XH
Zhonghua Nan Ke Xue; 2012 Nov; 18(11):982-5. PubMed ID: 23214246
[TBL] [Abstract][Full Text] [Related]
2. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
3. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
6. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Lam MG; de Klerk JM; Zonnenberg BA
J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.
Ricci S; Boni G; Pastina I; Genovesi D; Cianci C; Chiacchio S; Orlandini C; Grosso M; Alsharif A; Chioni A; Di Donato S; Francesca F; Selli C; Rubello D; Mariani G
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1023-30. PubMed ID: 17242920
[TBL] [Abstract][Full Text] [Related]
8. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
10. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
12. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
13. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
[TBL] [Abstract][Full Text] [Related]
14. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
15. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
Higano CS; Quick DP; Bushnell D; Sartor O
Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
[TBL] [Abstract][Full Text] [Related]
16. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
17. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results.
Kendler D; Donnemiller E; Oberladstätter M; Erler H; Gabriel M; Riccabona G
Nucl Med Commun; 2004 Apr; 25(4):367-73. PubMed ID: 15097811
[TBL] [Abstract][Full Text] [Related]
18. [Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer].
Ratsimanohatra H; Barlesi F; Doddoli C; Robitail S; Gimenez C; Kleisbauer JP; Astoul P
Rev Mal Respir; 2005 Apr; 22(2 Pt 1):317-20. PubMed ID: 16092169
[TBL] [Abstract][Full Text] [Related]
19. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
20. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]